Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| UMIN000011700 | Registry Identifier | UMIN |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to evaluate the efficacy and safety of eldecalcitol monotherapy compared with alfacalcidol monotherapy in patients with glucocorticoid-induced osteoporosis, using a randomized, open-label, parallel-group, comparative design.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Eldecalcitol group | Experimental | Eldecalcitol 0.75 microgram once daily orally |
|
| Alfacalcidol group | Active Comparator | Alfacalcidol 1 microgram once daily orally |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Eldecalcitol | Drug | Eldecalcitol 0.75 microgram once daily orally |
| |
| Measure | Description | Time Frame |
|---|---|---|
| Percent change in lumbar spine (L1-4) bone mineral density | 12 months after the start of study drug administration | |
| Incidence of vertebral fractures | A vertebral fracture will be classified as a new fracture (i.e., change from grade 0 to grade 1, 2, or 3) or worsening of a prevalent fracture (i.e., change from grade 1 to grade 2 or 3, or change from grade 2 to grade 3) using a semi-quantitative [SQ] method according to the "Vertebral Fracture Assessment Criteria, 2012 revised version." | 36 months |
| Measure | Description | Time Frame |
|---|---|---|
| Incidence of non-vertebral fractures (both traumatic and non-traumatic; All sites) | 36 months | |
| Incidence of non-vertebral fractures (both traumatic and non-traumatic; 3 Major sites) | The 3 Major sites are defined as the forearm, humerus, and femur. |
Not provided
Inclusion Criteria:
(1) Patients who are currently taking or plan to take oral glucocorticoid medication for 3 months or longer and thus require treatment as per the 'Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and mineral Research (2004),' and who meet at least one of the conditions below. No restriction is imposed on the underlying disease treated with the oral glucocorticoid medication.
(i) Have any existing insufficiency fracture (ii) %YAM <80 (iii) Oral glucocorticoid daily dose >= 5 mg prednisolone equivalent
(2) Aged between 20 and 85 years (both inclusive) at consent
(3) Patients who are able to walk without assistance
(4) Provided consent to participate in the study
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| e-GLORIA trial Office | Contact | +81-6229-8937 | e-gloria@mebix.co.jp |
| Name | Affiliation | Role |
|---|---|---|
| Toshio Matsumoto | University of Tokushima | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Nara Hospital Kinki University Faculty of Medicine | Recruiting | Ikoma | Nara | 630-0293 | Japan |
Not provided
| ID | Term |
|---|---|
| D010024 | Osteoporosis |
| ID | Term |
|---|---|
| D001851 | Bone Diseases, Metabolic |
| D001847 | Bone Diseases |
| D009140 | Musculoskeletal Diseases |
| D008659 | Metabolic Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C547512 | eldecalcitol |
| C008088 | alfacalcidol |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Alfacalcidol |
| Drug |
Alfacalcidol 1 microgram once daily orally |
|
| 36 months |
| Incidence of non-vertebral fractures (both traumatic and non-traumatic; 6 Major sites) | The 6 Major sites are defined as the femur, lower leg, humerus, forearm, clavicle, and pelvis. | 36 months |
| Incidence of non-vertebral fractures (traumatic; All sites) | 36 months |
| Incidence of non-vertebral fractures (traumatic; 3 Major sites) | 36 months |
| Incidence of non-vertebral fractures (traumatic; 6 Major sites) | 36 months |
| Incidence of non-vertebral fractures (non-traumatic; All sites) | 36 months |
| Incidence of non-vertebral fractures (non-traumatic; 3 Major sites） | 36 months |
| Incidence of non-vertebral fractures (non-traumatic; 6 Major sites） | 36 months |
| Incidence of vertebral fractures (new vertebral fractures) | 36 months |
| Incidence of vertebral fractures (worsening of prevalent vertebral fractures) | 36 months |
| Incidence of vertebral fractures (clinical vertebral fractures) | 36 months |
| Incidence of vertebral fracture (new or worsening of prevalent fractures) by glucocorticoid dose | 36 months |
| Incidence of clinical vertebral fractures by glucocorticoid dose | 36 months |
| Incidence of non-vertebral fractures (all sites) by glucocorticoid dose | 36 months |
| Incidence of non-vertebral fractures (3 Major sites) by glucocorticoid dose | 36 months |
| Incidence of non-vertebral fractures (6 Major sites) by glucocorticoid dose | 36 months |
| Incidence of vertebral fractures (new or worsening) by bone mineral density | 36 months |
| Incidence of clinical vertebral fractures by bone mineral density | 36 months |
| Incidence of non-vertebral fractures (all sites) by bone mineral density | 36 months |
| Incidence of non-vertebral fractures (3 Major sites) by bone mineral density | 36 months |
| Incidence of non-vertebral fractures (6 Major sites) by bone mineral density | 36 months |
| Incidence of vertebral fractures (new or worsening) by number of prevalent fractures | 36 months |
| Incidence of clinical vertebral fractures by number of prevalent fractures | 36 months |
| Incidence of non-vertebral fractures (all sites) by number of prevalent fractures | 36 months |
| Incidence of non-vertebral fractures (3 Major sites) by number of prevalent fractures | 36 months |
| Incidence of non-vertebral fractures (6 Major sites) by number of prevalent fractures | 36 months |
| Incidence of new vertebral fractures by severity | Semiquantitative (SQ) method is used for grading of vertebral fractures. | 36 months |
| Incidence of new clinical vertebral fractures by severity | SQ method is used for grading of vertebral fractures. | 36 months |
| Incidence of new non-vertebral fractures (all sites) by severity | SQ method is used for grading of vertebral fractures. | 36 months |
| Incidence of new non-vertebral fractures (3 Major sites) by severity | SQ method is used for grading of vertebral fractures. | 36 months |
| Incidence of new non-vertebral fractures (6 Major sites) by severity | 36 months |
| Incidence of osteoporotic fractures | An osteoporotic fracture is defined as a fracture of the following sites: vertebral body, ribs, pelvis, humerus, clavicle, scapula, sternum, proximal femur, other portions of the femur, tibia, fibula, and forearm. | 36 months |
| Incidence of FRAX-defined major osteoporotic fractures | The 4 Major sites are defined as clinical fractures of the spine, forearm, hip, and shoulder. | 36 months |
| Percent change in lumbar spine bone mineral density | 6 months after the start of study drug administration |
| Percent change in lumbar spine bone mineral density | 24 months after the start of study drug administration |
| Percent change in lumbar spine bone mineral density | 36 months after the start of study drug administration (or at the time of withdrawal from the study) |
| Change in proximal femur (total-hip) bone mineral density | 6 months after the start of study drug administration |
| Change in proximal femur (total-hip) bone mineral density | 12 months after the start of study drug administration |
| Change in proximal femur (total-hip) bone mineral density | 24 months after the start of study drug administration |
| Change in proximal femur (total-hip) bone mineral density | 36 months after the start of study drug administration (or at the time of withdrawal from the study) |
| Percent change in TRACP-5b bone metabolism marker | 6 months after the start of study drug administration |
| Percent change in TRACP-5b bone metabolism marker | 12 months after the start of study drug administration |
| Percent change in PINP bone metabolism marker | 6 months after the start of study drug administration |
| Percent change in PINP bone metabolism marker | 12 months after the start of study drug administration |
| Frequency of falls | 36 months |
| Change in muscle strength (back muscle strength) | 12 months after the start of study drug administration |
| Change in muscle strength (back muscle strength) | 24 months after the start of study drug administration |
| Change in muscle strength (back muscle strength) | 36 months after the start of study drug administration (or at the time of withdrawal from the study) |
| Change in muscle strength (grip strength) | 12 months after the start of study drug administration |
| Change in muscle strength (grip strength) | 24 months after the start of study drug administration |
| Change in muscle strength (grip strength) | 36 months after the start of study drug administration (or at the time of withdrawal from the study) |
| Change in height | 12 months after the start of study drug administration |
| Change in height | 24 months after the start of study drug administration |
| Change in height | 36 months after the start of study drug administration (or at the time of withdrawal from the study) |
| D009750 |
| Nutritional and Metabolic Diseases |